Orforglipron (30mg/50mg)

What is Orforglipron?

Orforglipron, also called LY3502970, is a small-molecule GLP-1 receptor agonist, not a peptide. This catalog offers 30mg and 50mg research vials. A laboratory vial is not the oral formulation studied clinically.

Listed vial contents: 30mg / 50mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Orforglipron activates GLP-1 receptors using non-peptide chemistry. Researchers can compare small-molecule and peptide receptor responses in controlled assays. Chemical class and formulation must both be considered when interpreting results.

What are the research questions?

• Small-molecule versus peptide GLP-1 receptor pharmacology
• Formulation-dependent behavior
• Separating cell-based receptor responses from clinical endpoints

What does the published work describe?

Wharton and colleagues' 2023 phase 2 trial studied an oral formulation in adults with obesity. Frías and colleagues' separate phase 2 trial studied adults with type 2 diabetes. These are human clinical studies of defined preparations, not evidence that a research vial is suitable for administration.

Experimental models in the cited papers

• Randomized phase 2 human obesity trial
• Randomized phase 2 human type 2 diabetes trial

What could future research explore?

Small-molecule GLP-1 activity opens questions about receptor interactions and formulation development. Potential future applications depend on evidence for a characterized preparation, not on its availability as a research reagent.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.

Study references

1. Wharton S, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023. PMID 37351564
2. Frías JP, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023. PMID 37369232

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.